We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more: https://bit.ly/4fjDBIP
Day One Biopharmaceuticals
Biotechnology Research
Brisbane, California 15,158 followers
Cancer drug development comes of age.
About us
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
- Website
-
http://www.dayonebio.com
External link for Day One Biopharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, California
- Type
- Public Company
- Founded
- 2018
- Specialties
- Oncology, Cancer, Drug Development, Biotechnology, Pediatric Oncology, Targeted Therapies, MAPK, Neuro-Oncology, Glioma, Childhood Cancer, Translational Medicine, Hematology, and Glioma
Locations
-
Primary
2000 Sierra Point Pkwy
Brisbane, California 94005, US
Employees at Day One Biopharmaceuticals
Updates
-
#WereHiring: Are you a Medical Affairs Leader open to exploring your next opportunity that will directly impact the field of adult and pediatric oncology drug development? We are seeking a dynamic leader to drive medical affairs strategy and who has an outstanding track record of building and leading high-performance organizations and partnerships as VP, Head of Medical Affairs. Apply here: https://bit.ly/3LxC3NU Or reach out to our Talent Acquisition team, Lindsey Summers 🎗💛, Jenny Lash, Ryan Sanders, to learn more. #Hiring #JoinOurTeam
-
Thank you to Simone Fishburn, BioCentury's Editor in Chief, for having our CEO, Jeremy Bender, on The #BioCenturyShow's recent episode to talk about Day One Biopharmaceuticals' approach to drug development and its strategy for long-term sustainability. Listen to the full episode here: https://bit.ly/3RYf560
On The #BioCenturyShow, Day One Biopharmaceuticals CEO Jeremy Bender joined BioCentury's Editor in Chief Simone Fishburn to talk: ➤ Pediatric cancer drug development, with opportunities for adult applications ➤ First v. best in class ➤ Advancements with ADCs ➤ How to turn a start-up into a commercial entity at lightening speed Watch the full interview now on YouTube or listen to "The BioCentury Show" on your favorite podcast platform: https://lnkd.in/gKkZuRqN Learn more: https://lnkd.in/gguT9TcA #drugdevelopment #pediatriccancer #ADCs
-
Day One welcomes the Pediatric Neuro-Oncology community to ISPNO! Connect with peers at our reception and hear from Day One leaders on the collaboration between academia and industry in advancing pediatric drug development. Learn more and register here: https://bit.ly/3xxJ6CC
-
Today, we announced the expansion of our pipeline with a clinical-stage antibody drug conjugate (ADC) targeting PTK7 in solid tumors for adult and pediatric cancers. DAY301 is an important continuation of our mission to transform outcomes for patients of all ages living with cancers. Learn more: https://lnkd.in/gg_jwggu
-
We recently published a framework for multistakeholder collaboration in pediatric cancer research and drug development based upon a case study of the tovorafenib journey. Co-authored by colleagues and collaborators, the framework specifies roles and responsibilities for effective collaboration between industry, academia, and non-profit organizations to bring new hope to children with cancer and their families. See the highlights below and access the full white paper here: https://bit.ly/4bYoLF7
-
It's great to be back at ASCO! Visit Day One at booth 34143 to say hello and learn more about how we are addressing the critical unmet need for children with brain tumors. #ASCO24
-
As #BrainTumorAwarenessMonth comes to an end, we are reminded of the urgent needs of those impacted by brain tumors. We are passionately #CommittedFromDayOne to increasing awareness for this community. Learn more: https://bit.ly/3wX29WU #BTAM #GoGrayinMay